Computer Guide Center

Anti Virus Protection News

Cameroon: UN Declares 2009 'Year of the Gorilla'Friday, January 9, 2009 @ 4:08PMThe United Nations Conservation of Migratory Species of Wild Animals has declared this year (2009) as the "Year of the Gorilla."The declaration is in a bid to help save our endangered 'primate cousins', the gorillas, from extinction.

Merck & Co., Inc. Receives Complete Response Letter from the Food and Drug Administration for Use of GARDASIL® in ...Friday, January 9, 2009 @ 7:39AM WHITEHOUSE STATION, N.J.----Merck & Co., Inc. announced today that the U.S. Food and Drug Administration has issued a second complete response letter regarding the supplemental biologics license application for the use of GARDASIL® [Human Papillomavirus Quadrivalent Vaccine, Recombinant ] in women ages 27 though 45.

Alnylam and Cubist Form Strategic Collaboration to Develop and Commercialize RNAi Therapeutics Targeting Respiratory ...Friday, January 9, 2009 @ 6:46AMCubist Pharmaceuticals, Inc., (Nasdaq: CBST), a leading acute care biopharmaceutical company, and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that they have formed a strategic collaboration to develop and commercialize Alnylam’s ALN-RSV program. The RSV-specific RNAi therapeutic program includes ALN-RSV01, which is currently in Phase II ...

Anti-Terrorism Council says 12 Philpost employees negative of anthrax on first swabbingFriday, January 9, 2009 @ 6:39AMMANILA, Jan. 9 (PNA)--Twelve Philippine Postal Corporation (Philpost) employees were quarantined and tested negative for anthrax virus, but the Anti-Terrorism Council (ATC) said they would wait for the result of further test to finally clear them.

Alnylam and Cubist Form Strategic Collaboration to Develop and Commercialize RNAi Therapeutics Targeting Respiratory ...Friday, January 9, 2009 @ 6:30AM LEXINGTON, Mass. & CAMBRIDGE, Mass.----Cubist Pharmaceuticals, Inc., , a leading acute care biopharmaceutical company, and Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that they have formed a strategic collaboration to develop and commercialize Alnylam’s ALN-RSV program.